← Browse by Condition
Medical Condition

graft versus host disease

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for graft versus host disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — graft versus host disease Clinical Trials

How many clinical trials are currently recruiting for graft versus host disease?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for graft versus host disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for graft versus host disease?
graft versus host disease research spans Phase 1 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a graft versus host disease clinical trial?
Eligibility criteria for graft versus host disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Top Sponsors
University of Wisconsin, Madison 1 trial
Massachusetts General Hospital 1 trial
Washington University School of Medicine 1 trial

Recruiting Clinical Trials

NCT06392711 Phase 1
Recruiting
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
Enrollment
36 pts
Location
United States
Sponsor
University of Wisconsin, Madis...
View Trial →
NCT06910969
Recruiting
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Enrollment
350 pts
Location
United States
Sponsor
Massachusetts General Hospital
View Trial →
NCT06008808 Phase 1
Recruiting
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Enrollment
41 pts
Location
United States
Sponsor
Washington University School o...
View Trial →

Related Conditions

xerostomia (1) sjogren s disease (1) bone marrow transplant complications (1) graft vs host disease (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology